65 jili Canada is to slap more tariffs on a range of imports from China early next year “to combat unfair Chinese trade practices,” the federal government said Monday in its 2024 Fall Economic Statement. Tariffs are to be put on certain Chinese imports including some solar products and critical minerals next year and on permanent magnets, natural graphite and semiconductors in 2026, Prime Minister Justin Trudeau’s government said. The measures will “prevent Chinese non-market trade practices from causing unfair and harmful market distortions in Canada and throughout the North American continent.” Details on the tariffs will follow in the 2025 Budget, it said. In October, Ottawa imposed a 100% tariff on all electric vehicles from China, as well as a 25% tariff on Chinese steel and aluminum products in response to what it describes as “the extraordinary threat to these sectors from unfair non-market competition, and insufficient or non-existent labour and environmental standards.” The government has also limited eligibility for federal zero-emission incentives to Canada’s free trade partners, Ottawa said in its fiscal update. “Canada will aggressively advance new measures to defend our economic security interests, as informed by Canadians' input received during consultations on potential new economic security measures,” the 2024 Fall Economic Statement read. “This includes developing a policy framework to mitigate risks posed by foreign entities owned, controlled, or influenced by a jurisdiction of concern, wherever they may operate,” the statement rea d. Those entities could be a channel for policies that harm Canada’s national or economic security, such as entities used to for state-driven ends or that benefit from non-market policies and suspicious practices conferring an unfair advantage competitive advantage over Canadian businesses, according to the statement. They could also exercise undue socio-economic political influence in host countries. In May, the government placed export controls on certain quantum computing and semiconductor technologies and equipment with potential military applications “to ensure their responsible development and transfer.” The fiscal update included two amendments that are critical to the mining sector. The first is the proposed expansion of eligibility for the Clean Technology Manufacturing investment tax credit (30%) to include the extraction of critical minerals from polymetallic mines in Canada. The tax credit, available since January, applied only to mines where 90% of the production value consisted of one or more of six critical minerals—nickel, copper, lithium, graphite, rare earth elements and cobalt. The credit thus could not be applied to polymetallic mines, which host copper, zinc, lead, molybdenum, gold and silver. “Of all existing copper mines and all known advanced projects, only one met the CTM-ITC as intended,” the Mining Association of Canada (MAC) said in a release on Monday. “The proposed amendment to lower the threshold to 50% retroactive to January 2024 will ensure that copper projects benefit from the CTM-ITC as intended.” “If the legislation is passed, the CTM-ITC will enable billions of dollars in new investment and the protection and creation of thousands of new jobs in at least four projects—one in Saskatchewan and three in British Columbia that, taken together, will increase Canada’s copper production by more than 50% and erase the significant decline in copper reserves that has occurred over the past 50 years.” A second proposed amendment in the fall economic assessment would also benefit junior miners that depend on critical flow-through share financings to support exploration, MAC added. Changes in the 2024 budget to the inclusion rate for capital gains had the “unintended consequence” of reducing the value of the Mineral Exploration Tax Credit (MTEC) to investors, MAC explained. “At a time when new investment in critical minerals exploration is most needed, it is estimated that of the $1.2 billion raised annually for exploration using the METC, $700-800 million will be lost if the METC is not fixed,” MAC said. “The proposed amendment to the Alternative Minimum Tax will largely restore the value of the METC and ensure investment dollars continue to support mineral exploration in Canada. Mining contributes $161 billion to Canada’s GDP and makes up 21% of the country’s total domestic exports.This Is The Average Stock Market Return Over 60 Years

Before the meeting was adjourned, council members Lou Martinez and Travis Paden were appointed as mayor and vice mayor, respectively, for a one-year term. The meeting began with recognition of former Councilmember Martin Devine, who was appointed to the District B seat earlier this year after the seat was vacated by Kalish Morrow. The District C seat was left vacant after former councilmember Diane Sharp resigned from her position in April. Devine was presented with a plaque for his service to the community and was thanked by his fellow council members for stepping in during a tumultuous time within the council. Devine shared some parting words before he was replaced on the dais. “I just want to say thank you to city staff and fellow council members, community members, friends and family. Thank you for your hard work, support, and collaboration during my appointment to the city council,” said Devine. “My fellow council members, thank you for your partnership and dedication to serving our city. To the members of our community, I'm deeply grateful for your trust, engagement, and passion for helping us move forward. Most of all, I want to express my deepest gratitude to the city staff. Your dedication to our community and your commitment to making sound decisions have been an inspiration and a testament to the strength of our city. Your hard work behind the scenes has been vital to addressing the challenges we face, making a meaningful difference for our residents. “I genuinely care about our city, and believe we are at a pivotal and crucial time that requires experienced and knowledgeable leadership. I pray that our city may continue to move forward positively guided by thoughtful leadership, a collaborative spirit, and a shared commitment to the successful growth of our city. Thank you, God bless, and congratulations to the newly-elected council members.” After a Resolution was approved accepting the election results, Howze and Regan were sworn in to their term in office. Individually, with Howze first and Regan last, City Clerk Natalie Corral led the women in the Oath of Office as the both recited her words with their right hands up in pledge. Both women signed their official paperwork before approaching the dais and shaking hands with their new colleagues. As their name placards were slid into place, Howze and Regan sank into their chairs, ready to get to work. “I think we're all excited to move forward,” said Regan. The first matter of business handled by the newly sat council was to nominate and appoint a new mayor and vice mayor for a one-year term. Regan was quick to nominate Councilmember Lou Martinez as mayor and Councilmember Travis Paden as vice mayor. Her nominations were supported across the dais. “I'm just looking forward to work as council together, a unified council, so that we can move forward and do what's in the best interest of our community, and improve the quality of life for all of us, not one group, but all of us together, and that's what I'm looking forward to doing,” said Martinez.

Clinical and regulatory success in 2024 expected to drive value in 2025 CRANFORD, N.J. , Dec. 27, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal full year ended September 30, 2024 . Fiscal Full Year 2024 Business Highlights and Subsequent Developments Achieved U.S. Food and Drug Administration (FDA) approval of LYMPHIRTM (denileukin diftitox-cxdl), an immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL); Advanced manufacturing, marketing and sales activities in preparation for commercial launch of LYMPHIR in the first half of 2025; Completed the merger of Citius Pharma's oncology subsidiary with TenX Keane to form Citius Oncology, Inc., a standalone publicly traded company which began trading on the Nasdaq exchange under the ticker symbol CTOR on August 13, 2024 ; Supported two investigator-initiated trials to explore LYMPHIR's potential as an immuno-oncology combination therapy being conducted at the University of Pittsburgh Medical Center and the University of Minnesota ; Shared interim trial results with the clinical community at the Society for Immunotherapy of Cancer Conference (SITC) of University of Pittsburgh Medical Center's Phase I trial of LYMPHIR with checkpoint inhibitor pembrolizumab; and, Met primary and secondary endpoints in the Phase 3 Pivotal Trial of Mino-Lok ® , demonstrating a statistically significant improvement in time to catheter failure of infected catheters compared to other physician-selected anti-infective lock solutions. Financial Highlights Cash and cash equivalents of $3.3 million as of September 30, 2024 ; R&D expenses were $11.9 million for the full year ended September 30, 2024 , compared to $14.8 million for the full year ended September 30, 2023 ; G&A expenses were $18.2 million for the full year ended September 30, 2024 , compared to $15.3 million for the full year ended September 30, 2023 ; Stock-based compensation expense was $11.8 million for the full year ended September 30, 2024 , compared to $6.6 million for the full year ended September 30, 2023 ; and, Net loss was $39.4 million , or ($5.97) per share for the full year ended September 30, 2024 compared to a net loss of $32.5 million , or ($5.57) per share for the full year ended September 30, 2023 . "In fiscal year 2024 we drove tremendous progress in our pipeline. It was a transformative year, marked by our first FDA approval and significant clinical milestones. The approval of LYMPHIRTM and the positive Phase 3 results for Mino-Lok® underscore our commitment to developing innovative therapies. Our team successfully responded to FDA comments related to the biologics license application for LYMPHIR and ultimately gained FDA approval. Productive engagement with the FDA regarding the positive results of our Phase 3 Mino-Lok® trial and Phase 2 Halo-Lido trial clarified our next steps for both programs. We anticipate continued engagement with the agency in the coming year and look forward to their guidance. Additionally, we are exploring strategic partnerships and licensing opportunities to maximize the potential of our portfolio and bring these important therapies to market efficiently," stated Leonard Mazur , Chairman and CEO of Citius Pharma. "Looking ahead, our priorities for fiscal year 2025 include launching LYMPHIRTM through our majority-owned subsidiary, Citius Oncology, driving the clinical and regulatory strategies for Mino-Lok® and Halo-Lido, fortifying our financial position, and applying a disciplined approach to resource allocation. We expect to launch LYMPHIR in the first half of 2025 and distribute CTOR shares to Citius Pharma shareholders by the end of the year, pending favorable market conditions. Our goal remains to deliver value for patients, healthcare providers, and shareholders. With a clear vision and a strong team, we are well-positioned to execute on our mission of bringing innovative therapies to market," added Mazur. FULL YEAR 2024 FINANCIAL RESULTS: Liquidity As of September 30, 2024 , the Company had $3.3 million in cash and cash equivalents. As of September 30, 2024 , the Company had 7,247,243 common shares outstanding, as adjusted for the 1-for-25 reverse stock split of the Company's common stock, effected on November 25, 2024 . During the year ended September 30, 2024 , the Company received net proceeds of $13.8 million from the issuance of equity. The Company expects to raise additional capital to support operations. Research and Development (R&D) Expenses R&D expenses were $11.9 million for the full year ended September 30, 2024 , compared to $14.8 million for the full year ended September 30, 2023 . The decrease in R&D expenses primarily reflects the completion of the Halo-Lido trial and completion of activities related to the regulatory resubmission for LYMPHIR, offset by shutdown costs associated with the end of the Phase 3 trial for Mino-Lok. We expect research and development expenses to decrease in fiscal year 2025 as we continue to focus on the commercialization of LYMPHIR through our majority-owned subsidiary, Citius Oncology and because we have completed the Phase 3 trial for Mino-Lok. General and Administrative (G&A) Expenses G&A expenses were $18.2 million for the full year ended September 30, 2024 , compared to $15.3 million for the full year ended September 30, 2023 . The increase was primarily due to costs associated with pre-launch and market research activities associated with LYMPHIR. General and administrative expenses consist primarily of compensation costs, professional fees for legal, regulatory, accounting and corporate development services, and investor relations expenses. Stock-based Compensation Expense For the full year ended September 30, 2024 , stock-based compensation expense was $11.8 million as compared to $6.6 million for the prior year. The increase of $5.2 million is largely due to the grant of options under the Citius Oncology stock plan. Stock-based compensation expense under the Citius Oncology stock plan was $7.5 million during the year ended September 30, 2024 , compared to $2.0 million for the year ended September 30, 2023 , as the plan was initiated in July 2023 . For the years ended September 30, 2024 and 2023, stock-based compensation expense also includes $47,547 and $130,382 , respectively, for the NoveCite stock option plan. In fiscal years 2023 and 2024, we granted options to our new employees and additional options to other employees, our directors, and consultants. Net loss Net loss was $39.4 million , or ($5.97) per share for the year ended September 30, 2024 , compared to a net loss of $32.5 million , or ($5.57) per share for the year ended September 30, 2023 , as adjusted for the reverse stock split. The increase in net loss reflects an increase in operating expense of $5.3 million offset by a decrease of $1.6 million in other income. Operating expense increased due to increases in stock-based compensation and general and administrative expenses, which were offset by decreased research and development expense. About Citius Pharmaceuticals, Inc. Citius Pharma is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. In August 2024 , the FDA approved LYMPHIRTM, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius Pharma's late-stage pipeline also includes Mino-Lok®, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 Trial. Citius Pharma is actively engaged with the FDA to outline next steps for both programs. For more information, please visit www.citiuspharma.com . Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Pharma. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Pharma are: our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to commercialize LYMPHIR through our majority-owned subisity and any of our other product candidates that may be approved by the FDA; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; risks related to research using our assets but conducted by third parties; risks relating to the results of research and development activities, including those from our existing and any new pipeline assets; our ability to maintain compliance with Nasdaq's continued listing standards; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; the early stage of products under development; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at www.sec.gov , including in Citius Pharma's Annual Report on Form 10-K for the year ended September 30, 2024 , filed with the SEC on December 27, 2024 , as updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. Investor Contact: Ilanit Allen ir@citiuspharma.com 908-967-6677 x113 Media Contact: STiR-communications Greg Salsburg Greg@STiR-communications.com -- Financial Tables Follow – CITIUS PHARMACEUTICALS, INC. CONSOLIDATED BALANCE SHEETS SEPTEMBER 30, 2024 AND 2023 2024 2023 ASSETS Current Assets: Cash and cash equivalents $ 3,251,880 $ 26,480,928 Inventory 8,268,766 — Prepaid expenses 2,700,000 7,889,506 Total Current Assets 14,220,646 34,370,434 Property and equipment, net — 1,432 Operating lease right-of-use asset, net 246,247 454,426 Other Assets: Deposits 38,062 38,062 In-process research and development 92,800,000 59,400,000 Goodwill 9,346,796 9,346,796 Total Other Assets 102,184,858 68,784,858 Total Assets $ 116,651,751 $ 103,611,150 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable $ 4,927,211 $ 2,927,334 License payable 28,400,000 — Accrued expenses 17,027 476,300 Accrued compensation 2,229,018 2,156,983 Operating lease liability 241,547 218,380 Total Current Liabilities 35,814,803 5,778,997 Deferred tax liability 6,713,800 6,137,800 Operating lease liability – non current 21,318 262,865 Total Liabilities 42,549,921 12,179,662 Commitments and Contingencies Stockholders' Equity: Preferred stock - $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding — — Common stock - $0.001 par value; 16,000,000 shares authorized; 7,247,243 and 6,354,371 shares issued and outstanding at September 30, 2024 and 2023, respectively 7,247 6,354 Additional paid-in capital 271,440,421 253,056,133 Accumulated deficit (201,370,218) (162,231,379) Total Citius Pharmaceuticals, Inc. Stockholders' Equity 70,077,450 90,831,108 Non-controlling interest 4,024,380 600,380 Total Equity 74,101,830 91,431,488 Total Liabilities and Equity $ 116,651,751 $ 103,611,150 Reflects a 1-for-25 reverse stock split effective November 25, 2024. CITIUS PHARMACEUTICALS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 2024 2023 Revenues $ — $ — Operating Expenses: Research and development 11,906,601 14,819,729 General and administrative 18,249,402 15,295,584 Stock-based compensation – general and administrative 11,839,678 6,616,705 Total Operating Expenses 41,995,681 36,732,018 Operating Loss (41,995,681) (36,732,018) Other Income: Interest income, net 758,000 1,179,417 Gain on sale of New Jersey net operating losses 2,387,842 3,585,689 Total Other Income Net 3,145,842 4,765,106 Loss before Income Taxes (38,849,839) (31,966,912) Income tax expense 576,000 576,000 Net Loss (39,425,839) (32,542,912) Net loss attributable to non-controlling interest 287,000 - Deemed dividend on warrant extension (1,047,312) (1,151,208) Net Loss Applicable to Common Stockholders $ (40,186,151) (33,694,120) Net Loss Per Share Applicable to Common Stockholders - Basic and Diluted $ (5.97) (5.57) Weighted Average Common Shares Outstanding

MEN'S COLLEGE BASKETBALL 11 a.m., Md.-Eastern Shore at Maryland;BTN 11 a.m., E. Kentucky at Louisville;CW 11 a.m., Coppin St. at Georgetown;FS1 1 p.m., Alabama A&M at Georgia Tech;ACCN 1 p.m., NC Central at NC ACBS 1 p.m., Bucknell at SyracuseCW 1 p.m., Mississippi at Memphis;ESPN2 1 p.m., Loyola (Md.) at DePaul;FS1 3 p.m., Fairleigh Dickinson at Boston College;ACCN 3 p.m., Howard at Hampton;CBS 3 p.m., UCLA vs. Gonzaga, Los Angeles;FOX 3 p.m., Abilene Christian at Texas ASECN 5 p.m., Utah St. at San Diego St.;FOX 5 p.m., Delaware at St. John’s;FS1 WOMEN'S COLLEGE BASKETBALL 12:30 p.m., Creighton at St. John’s;FOX 1 p.m., Wisconsin at Indiana;BTN 3 p.m., Penn St. at Minnesota;BTN 3 p.m., Oregon St. at Gonzaga;ESPN2 COLLEGE FOOTBALL 10 a.m., The Wasabi Fenway Bowl: UConn vs. North Carolina, Boston;ESPN 11 a.m., The Bad Boy Mowers Pinstripe Bowl: Boston College vs. Nebraska, New York;ABC 1:15 p.m., The Isleta New Mexico Bowl: Louisiana-Lafayette vs. TCU, Albuquerque, N.M.;ESPN 2:30 p.m., The Pop-Tarts Bowl: Iowa St. vs. Miami, Orlando, Fla.;ABC 3:15 p.m., The Snoop Dogg Arizona Bowl: Miami (Ohio) vs. Colorado St., Tucson, Ariz.;CW 4:45 p.m., The Go Bowling Military Bowl: East Carolina vs. NC State, Annapolis, Md.;ESPN 6:30 p.m., The Valero Alamo Bowl: BYU vs. Colorado, San Antonio;ABC 8:15 p.m., The Radiance Technologies Independence Bowl: Louisiana Tech vs. Army, Shreveport, La.;ESPN NBA 2 p.m., Miami at Atlanta;NBATV 5 p.m., Oklahoma City at Charlotte;NBATV 7 p.m., Milwaukee at Chicago;CHSN 7:30 p.m., Phoenix at Golden State;NBATV NFL Noon, L.A. Chargers at New England;NFLN 3:30 p.m., Denver at Cincinnati;NFLN 7 p.m., Arizona at L.A. Chargers;NFLN NHL 6 p.m., Washington at Toronto;NHLN SUNDAY MEN'S COLLEGE BASKETBALL 11 a.m., Indiana St. at Ohio St.;BTN Noon, Penn at Penn St.;PEACOCK 12:30 p.m., Northeastern at Northwestern;PEACOCK 1 p.m., Chicago St. at Illinois;BTN 1 p.m., Morgan St. at Minnesota;PEACOCK 2 p.m., Buffalo at Temple;ESPNU 2 p.m., NJIT at Washington;PEACOCK 3 p.m., Winthrop at Indiana;BTN 5 p.m., Toledo at Purdue;BTN 7 p.m., Campbell at North Carolina;ACCN 7 p.m., W. Kentucky at Michigan;BTN WOMEN'S COLLEGE BASKETBALL Noon, South Florida at Rice;ESPN2 1 p.m., Wofford at South Carolina;SECN 9 p.m., Michigan at Southern Cal;BTN NFL Noon, N.Y. Jets at Buffalo;CBS Noon, Dallas at Philadelphia;FOX 3:25 p.m., Green Bay at Minnesota;FOX 7:20 p.m., Atlanta at Washington;NBC, PEACOCK NHL 2 p.m., Buffalo at St. Louis;FDSMW 7:30 p.m., Dallas at Chicago;ESPN MEN'S SOCCER 9 a.m., Premier League: Nottingham Forest at Everton;USA 11:15 a.m., Premier League: Liverpool at West Ham United;USA MONDAY MEN'S COLLEGE BASKETBALL 2 p.m., W. Michigan at Michigan St.;BTN 4 p.m., Columbia at Rutgers;BTN 6 p.m., New Hampshire at Iowa;BTN 6 p.m., Cincinnati at Kansas St.;CBSSN 7 p.m., Oakland at Arkansas;ESPN2 8 p.m., Southern U. at Nebraska;BTN 8 p.m., Iowa St. at Colorado;CBSSN COLLEGE FOOTBALL 1:30 p.m., The TransPerfect Music City Bowl: Iowa vs. Missouri, Nashville, Tenn.;ESPN NBA 6 p.m., Chicago at Charlotte;CHSN 6 p.m., New York at Washington;NBATV 9 p.m., Dallas at Sacramento;NBATV NHL 6 p.m., N.Y. Rangers at Florida;NHLN MEN'S SOCCER 2 p.m., Premier League: Newcastle United at Manchester United;USA

Clinical and regulatory success in 2024 expected to drive value in 2025 CRANFORD, N.J. , Dec. 27, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal full year ended September 30, 2024 . Fiscal Full Year 2024 Business Highlights and Subsequent Developments Financial Highlights "In fiscal year 2024 we drove tremendous progress in our pipeline. It was a transformative year, marked by our first FDA approval and significant clinical milestones. The approval of LYMPHIRTM and the positive Phase 3 results for Mino-Lok® underscore our commitment to developing innovative therapies. Our team successfully responded to FDA comments related to the biologics license application for LYMPHIR and ultimately gained FDA approval. Productive engagement with the FDA regarding the positive results of our Phase 3 Mino-Lok® trial and Phase 2 Halo-Lido trial clarified our next steps for both programs. We anticipate continued engagement with the agency in the coming year and look forward to their guidance. Additionally, we are exploring strategic partnerships and licensing opportunities to maximize the potential of our portfolio and bring these important therapies to market efficiently," stated Leonard Mazur , Chairman and CEO of Citius Pharma. "Looking ahead, our priorities for fiscal year 2025 include launching LYMPHIRTM through our majority-owned subsidiary, Citius Oncology, driving the clinical and regulatory strategies for Mino-Lok® and Halo-Lido, fortifying our financial position, and applying a disciplined approach to resource allocation. We expect to launch LYMPHIR in the first half of 2025 and distribute CTOR shares to Citius Pharma shareholders by the end of the year, pending favorable market conditions. Our goal remains to deliver value for patients, healthcare providers, and shareholders. With a clear vision and a strong team, we are well-positioned to execute on our mission of bringing innovative therapies to market," added Mazur. FULL YEAR 2024 FINANCIAL RESULTS: Liquidity As of September 30, 2024 , the Company had $3.3 million in cash and cash equivalents. As of September 30, 2024 , the Company had 7,247,243 common shares outstanding, as adjusted for the 1-for-25 reverse stock split of the Company's common stock, effected on November 25, 2024 . During the year ended September 30, 2024 , the Company received net proceeds of $13.8 million from the issuance of equity. The Company expects to raise additional capital to support operations. Research and Development (R&D) Expenses R&D expenses were $11.9 million for the full year ended September 30, 2024 , compared to $14.8 million for the full year ended September 30, 2023 . The decrease in R&D expenses primarily reflects the completion of the Halo-Lido trial and completion of activities related to the regulatory resubmission for LYMPHIR, offset by shutdown costs associated with the end of the Phase 3 trial for Mino-Lok. We expect research and development expenses to decrease in fiscal year 2025 as we continue to focus on the commercialization of LYMPHIR through our majority-owned subsidiary, Citius Oncology and because we have completed the Phase 3 trial for Mino-Lok. General and Administrative (G&A) Expenses G&A expenses were $18.2 million for the full year ended September 30, 2024 , compared to $15.3 million for the full year ended September 30, 2023 . The increase was primarily due to costs associated with pre-launch and market research activities associated with LYMPHIR. General and administrative expenses consist primarily of compensation costs, professional fees for legal, regulatory, accounting and corporate development services, and investor relations expenses. Stock-based Compensation Expense For the full year ended September 30, 2024 , stock-based compensation expense was $11.8 million as compared to $6.6 million for the prior year. The increase of $5.2 million is largely due to the grant of options under the Citius Oncology stock plan. Stock-based compensation expense under the Citius Oncology stock plan was $7.5 million during the year ended September 30, 2024 , compared to $2.0 million for the year ended September 30, 2023 , as the plan was initiated in July 2023 . For the years ended September 30, 2024 and 2023, stock-based compensation expense also includes $47,547 and $130,382 , respectively, for the NoveCite stock option plan. In fiscal years 2023 and 2024, we granted options to our new employees and additional options to other employees, our directors, and consultants. Net loss Net loss was $39.4 million , or ($5.97) per share for the year ended September 30, 2024 , compared to a net loss of $32.5 million , or ($5.57) per share for the year ended September 30, 2023 , as adjusted for the reverse stock split. The increase in net loss reflects an increase in operating expense of $5.3 million offset by a decrease of $1.6 million in other income. Operating expense increased due to increases in stock-based compensation and general and administrative expenses, which were offset by decreased research and development expense. About Citius Pharmaceuticals, Inc. Citius Pharma is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. In August 2024 , the FDA approved LYMPHIRTM, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius Pharma's late-stage pipeline also includes Mino-Lok®, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 Trial. Citius Pharma is actively engaged with the FDA to outline next steps for both programs. For more information, please visit www.citiuspharma.com . Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Pharma. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Pharma are: our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to commercialize LYMPHIR through our majority-owned subisity and any of our other product candidates that may be approved by the FDA; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; risks related to research using our assets but conducted by third parties; risks relating to the results of research and development activities, including those from our existing and any new pipeline assets; our ability to maintain compliance with Nasdaq's continued listing standards; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; the early stage of products under development; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at www.sec.gov , including in Citius Pharma's Annual Report on Form 10-K for the year ended September 30, 2024 , filed with the SEC on December 27, 2024 , as updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. Investor Contact: Ilanit Allen ir@citiuspharma.com 908-967-6677 x113 Media Contact: STiR-communications Greg Salsburg Greg@STiR-communications.com -- Financial Tables Follow – CITIUS PHARMACEUTICALS, INC. CONSOLIDATED BALANCE SHEETS SEPTEMBER 30, 2024 AND 2023 2024 2023 ASSETS Current Assets: Cash and cash equivalents $ 3,251,880 $ 26,480,928 Inventory 8,268,766 — Prepaid expenses 2,700,000 7,889,506 Total Current Assets 14,220,646 34,370,434 Property and equipment, net — 1,432 Operating lease right-of-use asset, net 246,247 454,426 Other Assets: Deposits 38,062 38,062 In-process research and development 92,800,000 59,400,000 Goodwill 9,346,796 9,346,796 Total Other Assets 102,184,858 68,784,858 Total Assets $ 116,651,751 $ 103,611,150 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable $ 4,927,211 $ 2,927,334 License payable 28,400,000 — Accrued expenses 17,027 476,300 Accrued compensation 2,229,018 2,156,983 Operating lease liability 241,547 218,380 Total Current Liabilities 35,814,803 5,778,997 Deferred tax liability 6,713,800 6,137,800 Operating lease liability – non current 21,318 262,865 Total Liabilities 42,549,921 12,179,662 Commitments and Contingencies Stockholders' Equity: Preferred stock - $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding — — Common stock - $0.001 par value; 16,000,000 shares authorized; 7,247,243 and 6,354,371 shares issued and outstanding at September 30, 2024 and 2023, respectively 7,247 6,354 Additional paid-in capital 271,440,421 253,056,133 Accumulated deficit (201,370,218) (162,231,379) Total Citius Pharmaceuticals, Inc. Stockholders' Equity 70,077,450 90,831,108 Non-controlling interest 4,024,380 600,380 Total Equity 74,101,830 91,431,488 Total Liabilities and Equity $ 116,651,751 $ 103,611,150 Reflects a 1-for-25 reverse stock split effective November 25, 2024. CITIUS PHARMACEUTICALS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 2024 2023 Revenues $ — $ — Operating Expenses: Research and development 11,906,601 14,819,729 General and administrative 18,249,402 15,295,584 Stock-based compensation – general and administrative 11,839,678 6,616,705 Total Operating Expenses 41,995,681 36,732,018 Operating Loss (41,995,681) (36,732,018) Other Income: Interest income, net 758,000 1,179,417 Gain on sale of New Jersey net operating losses 2,387,842 3,585,689 Total Other Income Net 3,145,842 4,765,106 Loss before Income Taxes (38,849,839) (31,966,912) Income tax expense 576,000 576,000 Net Loss (39,425,839) (32,542,912) Net loss attributable to non-controlling interest 287,000 - Deemed dividend on warrant extension (1,047,312) (1,151,208) Net Loss Applicable to Common Stockholders $ (40,186,151) (33,694,120) Net Loss Per Share Applicable to Common Stockholders - Basic and Diluted $ (5.97) (5.57) Weighted Average Common Shares OutstandingTrump asks Supreme Court to delay TikTok ban so he can weigh in after he takes office